82 FR 56624 - National Institute on Aging; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 228 (November 29, 2017)

Page Range		56624-56624
FR Document		2017-25734

Federal Register, Volume 82 Issue 228 (Wednesday, November 29, 2017)

[Federal Register Volume 82, Number 228 (Wednesday, November 29, 2017)]
[Notices]
[Page 56624]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-25734]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Aging; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Aging Special Emphasis 
Panel; AD Sequencing II.
    Date: December 1, 2017.
    Time: 1:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute on Aging, Gateway Building, Suite 
2C212, 7201 Wisconsin Avenue, Bethesda, MD 20814 (Telephone 
Conference Call).
    Contact Person: Bita Nakhai, Ph.D., Scientific Review Branch, 
National Institute on Aging, Gateway Bldg., 2C212, 7201 Wisconsin 
Avenue, Bethesda, MD 20814, 301-402-7701, [email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging 
Research, National Institutes of Health, HHS)

    Dated: November 22, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-25734 Filed 11-28-17; 8:45 am]
 BILLING CODE 4140-01-P

56624 Federal Register / Vol. 82, No. 228 / Wednesday, November 29, 2017 / Notices

Serial No. 201737032671, filed on 09/ under the Freedom of Information Act, DEPARTMENT OF HEALTH AND
14/2017. 5 U.S.C. 552. HUMAN SERVICES
All rights in these inventions have Suzanne Frisbie, National Institutes of Health
been assigned to the Government of the Deputy Director, Technology Transfer and
United States of America. Intellectual Property Office, National Institute National Center for Advancing
The prospective exclusive patent of Allergy and Infectious Diseases. Translational Sciences; Notice of
commercialization license territory may [FR Doc. 2017–25745 Filed 11–28–17; 8:45 am] Meetings
be worldwide and the field of use may BILLING CODE 4140–01–P Pursuant to section 10(d) of the
be limited to: ‘‘Administration to Federal Advisory Committee Act, as
humans of a GP120-binding protein or amended, notice is hereby given of
proteins, containing the 6 CDRs of the DEPARTMENT OF HEALTH AND meetings of the National Center for
N6 antibody, all as described in the HUMAN SERVICES Advancing Translational Sciences.
Licensed Patent Rights. This field of use The meetings will be open to the
does not include bi-specific/multi- National Institutes of Health public as indicated below, with
specific constructs utilizing the attendance limited to space available.
Licensed Patent Rights.’’ National Institute on Aging; Notice of
Individuals who plan to attend and
Closed Meeting
The N6 antibody has evolved a need special assistance, such as sign
unique mode of binding that depends Pursuant to section 10(d) of the language interpretation or other
less on a variable area of the HIV Federal Advisory Committee Act, as reasonable accommodations, should
envelope known as the V5 region and notify the Contact Person listed below
amended, notice is hereby given of the
focuses more on conserved regions, in advance of the meeting.
following meeting. The meetings will be closed to the
which change relatively little among
The meeting will be closed to the public in accordance with the
HIV strains. This allows N6 to tolerate
changes in the HIV envelope, including public in accordance with the provisions set forth in sections
the attachment of sugars in the V5 provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
region, a major mechanism by which 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and
as amended. The grant applications and the discussions could disclose
HIV develops resistance to other VRC01-
the discussions could disclose confidential trade secrets or commercial
class antibodies. N6 was shown in pre-
confidential trade secrets or commercial property such as patentable material,
clinical studies to neutralize
property such as patentable material, and personal information concerning
approximately 98 percent of HIV
and personal information concerning individuals associated with the grant
isolates tested. The studies also applications, the disclosure of which
demonstrate that N6 neutralizes individuals associated with the grant
applications, the disclosure of which would constitute a clearly unwarranted
approximately 80 percent of HIV invasion of personal privacy.
isolates which were resistant to other would constitute a clearly unwarranted
antibodies of the same class, and does invasion of personal privacy. Name of Committee: Cures Acceleration
Network Review Board.
so very potently. Its breadth and Name of Committee: National Institute on Date: January 11, 2018.
potency makes N6 a highly desirable Aging Special Emphasis Panel; AD Time: 8:30 a.m. to 3:00 p.m.
candidate for development in Sequencing II. Agenda: Report from the Institute Director.
therapeutic or prophylactic strategies. Date: December 1, 2017. Place: National Institutes of Health,
An abstract of the subject invention was Time: 1:00 p.m. to 5:00 p.m. Building 31, Conference Room 10, 31 Center
published in the Federal Register on Agenda: To review and evaluate grant Drive, Bethesda, MD 20892.
applications. Contact Person: Anna L. Ramsey-Ewing,
March 13, 2017.
Place: National Institute on Aging, Ph.D., Executive Secretary, National Center
This notice is made in accordance Gateway Building, Suite 2C212, 7201 for Advancing Translational Sciences, 1
with 35 U.S.C. 209 and 37 CFR part 404. Wisconsin Avenue, Bethesda, MD 20814 Democracy Plaza, Room 1072, Bethesda, MD
The prospective exclusive patent 20892, 301–435–0809, anna.ramseyewing@
(Telephone Conference Call).
commercialization license will be nih.gov.
Contact Person: Bita Nakhai, Ph.D.,
royalty bearing and may be granted Scientific Review Branch, National Institute Name of Committee: National Center for
unless within fifteen (15) days from the Advancing Translational Sciences Advisory
on Aging, Gateway Bldg., 2C212, 7201
Council.
date of this published notice, the Wisconsin Avenue, Bethesda, MD 20814, Date: January 11, 2018.
National Institute of Allergy and 301–402–7701, nakhaib@nia.nih.gov. Open: 8:30 a.m. to 3:00 p.m.
Infectious Diseases receives written This notice is being published less than 15 Agenda: Report from the Institute Director
evidence and argument that establishes days prior to the meeting due to the timing and other staff.
that the grant of the license would not limitations imposed by the review and Place: National Institutes of Health,
be consistent with the requirements of funding cycle. Building 31, Conference Room 10, 31 Center
35 U.S.C. 209 and 37 CFR part 404. Drive, Bethesda, MD 20892.
(Catalogue of Federal Domestic Assistance Closed: 3:15 p.m. to 4:30 p.m.
Complete applications for a license in Program Nos. 93.866, Aging Research, Agenda: To review and evaluate grant
the prospective field of use that are National Institutes of Health, HHS) applications.
pmangrum on DSK3GDR082PROD with NOTICES1

timely filed in response to this notice Dated: November 22, 2017. Place: National Institutes of Health,
will be treated as objections to the grant Building 31, Conference Room 10, 31 Center
Melanie J. Pantoja, Drive, Bethesda, MD 20892.
of the contemplated exclusive patent
Program Analyst, Office of Federal Advisory Contact Person: Anna L. Ramsey-Ewing,
commercialization license. Comments Committee Policy. Ph.D., Executive Secretary, National Center
and objections submitted in response to for Advancing Translational Sciences, 1
[FR Doc. 2017–25734 Filed 11–28–17; 8:45 am]
this notice will not be made available Democracy Plaza, Room 1072, Bethesda, MD
BILLING CODE 4140–01–P
for public inspection and, to the extent 20892, 301–435–0809, anna.ramseyewing@
permitted by law, will not be released nih.gov.

VerDate Sep<11>2014 15:19 Nov 28, 2017 Jkt 241001 PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 E:\FR\FM\29NON1.SGM 29NON1

Document Created: 2017-11-29 01:26:33
Document Modified: 2017-11-29 01:26:33

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		December 1, 2017.
FR Citation		82 FR 56624

82 FR 56624 - National Institute on Aging; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 82, Issue 228 (November 29, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health